Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Arcturus Therapeutics Stock Is Plunging Today

By Keith Speights - Dec 29, 2020 at 11:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced disappointing early stage results for its single-dose COVID-19 vaccine candidate.

What happened

Shares of Arcturus Therapeutics Holdings ( ARCT -3.02% ) were plunging 53.7% as of 11:16 a.m. EST on Tuesday. The huge decline came after the biotech reported data from an early-stage clinical study of COVID-19 vaccine candidate ARCT-021.

So what

Investors had high hopes that a single dose of ARCT-021 could be highly effective at preventing infection by the coronavirus that causes COVID-19. But Arcturus' latest results poured cold water on those expectations.

Gloved hand holding vaccine vial with syringe and needle

Image source: Getty Images.

Arcturus reported that its vaccine produced neutralizing antibodies after only one dose. But the levels of the neutralizing antibodies were lower than those produced by Pfizer's and Moderna's two-dose COVID-19 vaccines.

Raymond James analyst Steven Seedhouse stated in a note to the firm's clients that the efficacy for ARCT-021 with a single dose could be as low as 62%. That's a disappointing level compared to Pfizer's efficacy of 95% and Moderna's 94%.

It's possible that a two-dose regimen of ARCT-021 could be much more effective. But it wouldn't give Arcturus a competitive advantage over rivals like a highly effective single-dose vaccine would. There's also at least a possibility that further clinical studies will show that a single dose of ARCT-021 does generate a higher efficacy than the early-stage results appear to indicate. For now, though, much of the excitement about Arcturus' prospects have understandably fizzled.

Now what

Arcturus received approval from regulators in Singapore to advance ARCT-021 to a phase 2 clinical study. The company anticipates reporting interim results from this study in early 2021 and beginning a global phase 3 study in the second quarter of next year. The biotech stock probably won't have any significant chances of rebounding unless the results from these studies are much better than the early-stage data.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arcturus Therapeutics Holdings Inc. Stock Quote
Arcturus Therapeutics Holdings Inc.
ARCT
$38.14 (-3.02%) $-1.19
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.90 (0.96%) $0.49
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$280.08 (-1.17%) $-3.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
652%
 
S&P 500 Returns
145%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/09/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.